MHRA-101583-PIP01-24-M01 (update)

Key Facts

Active Substance
Active Substance:
  • Recombinant Varicella Zoster Virus Glycoprotein E
Invented Name
  • Shingrix
  • Shingrix
  • Shingrix
  • Shingrix
PIP Number MHRA-101583-PIP01-24-M01 (update)
Pharmaceutical form(s)
  • powder and suspension for suspension for injection
  • Suspension for injection
Therapeutic area
Therapeutic area:
  • Vaccines
Conditions / Indications
Conditions / Indications:
  • Prevention of varicella zoster virus (VZV) reactivation
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Recombinant Varicella Zoster Virus Glycoprotein E.pdf
Published Date 06/01/2025